Diamyd, Inc. (formerly Nurel Therapeutics)
Diamyd, Inc. was formed through the acquisition of Nurel Therapeutics in December 2005 and is the wholly-owned US subsidiary of Diamyd Medical AB, a publicly traded company based in Stockholm, Sweden. Diamyd Medical’s lead product, Diamyd®, is a novel protein therapy for the prevention of the onset of diabetes and is currently in two Phase 2 clinical trials in Sweden. At its Pittsburgh location, Diamyd is developing novel products for the treatment of diabetes and its complications including chronic pain and diabetic neuropathy. Diamyd’s proprietary nerve targeting delivery system was developed at the University of Pittsburgh and has numerous additional applications including potential therapies for the treatment of cancer and central nervous systems disorders.